The vitellogenin genes of Xenopus are llver-specifically expressed. An in vitro transcription system derived from rat liver nuclei allowed us to define the cis-element BABS (B-activator binding site) in the promoter of the B1 vitellogenin gene. An oligonucleotide encompassing the region from -53 to -44 linked to a TATA box is sufficient for a tenfold increase of the transcriptional activity. Gel retardation assays with nuclear rat liver proteins reveal two DNA-protein complexes: Complex 1 can be competed by the USF/MLTF binding site of the adeno major late promoter whereas complex 2 is a distinct protein we refer to as BAP (B-actlvator protein). In vitro transcription experiments in the presence of USF/MLTF binding site as competitor show that BAP is an efficient transcription factor. Based on UV crosslinking we estimate that BAP has a molecular weight of 58 kd. Phosphatase treatment reveals that DNA binding of BAP requires phosphorylation. BABS is also present in the hepatitis B virus enhancer suggesting that it might play a role in the tumorigenic potential of the virus.
INTRODUCTION
Transcriptional control of gene expression is the major mechanism involved in regulating gene activities in eukaryotes. This process is largely based on the interaction of transcription factors with short stretches of DNA sequences in the promoters and enhancers (1, 2) . It is concievable that the activity of a given gene is regulated by the presence of various cis-elements and the availability of transcription factors interacting with these regulatory elements. To elucidate regulatory processes it is essential to define the various cis-elements and their corresponding trans-acting factors.
The four vitellogenin genes Al, A2, Bl and B2 of Xenopus provide a unique system for studying cis-elements and trans-acting factors involved in estrogen inducible, liver-specific and developmentally regulated gene expression (3, 4) . As it has well been established that trans-acting factors and the corresponding cis-elements have been conserved during evolution (5) , regulatory elements can be described in heterologous systems. Using such an approach, we have identified in frog genes regulatory elements functioning in mammalian cells: The albumin promoter contains HP1, a regulatory element conferring liver-specific gene expression (6) and this regulatory element corresponds to the LFB1/HNF1 binding site identified in mammalian genes specifically expressed in hepatocytes (7, 8, 9, 10) . The vitellogenin genes contain an estrogen responsive element (11, 12) and a cell-specific activator binding site (11, 13) functioning in mammalian cells. The cell-specific activator binding site has been identified in the promoter of the A2 vitellogenin gene. As the A and B vitellogenin genes of Xenopus are coordinately expressed (14) , we have looked for a corresponding regulatory element in the other vitellogenin genes.
In this report we describe the characterization of a transcriptional regulatory element (BABS) of the Xenopus B1 vitellogenin gene which is distinct from previously described regulatory elements. Using extracts from rat liver nuclei we have characterized the corresponding trans-acting factor, BAP.
MATERIALS AND METHODS
Crude rat liver nuclear extract was prepared from male Sprague-Dawley rats as described by Gorski et al. (15) with the following modifications: (1) Just prior to use, the protease inhibitors pepstatin A and leupeptin (1 /tg/ml each) as well as benzamidine and PMSF (phenylmethylsulfonyl fluoride; 0.1 mM each) were added to all buffers used in the nuclear isolation and protein purification procedure. ( 2) The tissue homogenate was centrifuged only once at 24,000 rpm for 60 min in an SW 27 rotor. Protein concentration was determined according to Lowry (16) .
Nuclear extract from 20 rat livers (about 200 mg protein) was applied to a Q-Sepharose FF matrix column (1.6x12 cm) preequilibrated with dialysis buffer (buffer D = 25 mM HEPES, 40 mM NaCl, 0.1 mM EDTA, 10% glycerol, 1 mM DTT, pH 7.6) with 20 mM sodium molybdate and 0.1 % Nonidet P^40. Fractions were analyzed for BAP activity by a gel shift assay. The flowthrough, containing the BAP activity, was precipitated with ammonium sulfate (0.3 g/ml) and applied to a heparinSepharose CL-6B matrix column (1.6x8 cm) in buffer D. The column was washed with 100 ml of buffer D and proteins eluted with a 200 ml step gradient of NaCl (0.3, 0.6, 0.9, 1.2 M). BAP activity eluting at 0.6 M was dialyzed against buffer Z (25 mM HEPES, 0.1 M NaCl, 12.5 mM MgCl 2 , 1 mM DTT, 20% glycerol and 0.1% Nonidet P-40, pH 7.8), containing 20 mM sodium molybdate and chromatographed on a DNA affinity column. The DNA affinity column was prepared as described by Kadonaga and Tjian (17) , using CNBr-activated Sepharose CL-4B and multimers of a synthetic B-activator binding site, prepared by annealing and ligating the two oligonucleotides: 5' AGCTTGGTGCACATGCGCCA 3' and 5' GAT-CTGGCGCATGTGCACCA 3'. Heparin-Sepharose-purified BAP was incubated with sonicated salmon sperm DNA (5 /ig/ml) and loaded onto the DNA affinity column equilibrated with buffer Z. Proteins were step eluted with buffer Z containing increasing amounts of NaCl. Active fractions were pooled and reapplied twice to the same affinity column without adding any unspecific competitor DNA. Proteins were analyzed on 10% SDS-polyacrylamide gels according to Laemmli (18) and silver stained as described by Wray et al. (19) .
Phosphatase treatment was done as described by Boxer et al. (20) . Where indicated Na2MoO4 at a final concentration of 20 mM was added before addition of potato acid phosphatase.
In vitro transcription reactions were performed as previously described (13, 21) , using nuclear extract from rat liver. The transcription templates were generated by insertion of HindHI/BamHI fragments into PL-TG (6) . Bal 31 deletions were constructed as described (11) . Oligonucleotides synthesized on a Pharmacia Gene Assembler were annealed and cloned without further purifications. All plasmid constructs were verified by sequencing of the relevant portion using the method described by Chen et al. (22) .
For band shift experiments, the probes were labeled by fill in using E. coli polymerase I (Klenow) with the appropriate radioactive deoxynucleotide triphosphates. 3-5 ng nuclear proteins from rat liver were incubated in 15 /J of 10 mM HEPES, 60 mM KC1, 1 mM EDTA, 1 mM DTT, 4% Ficoll, pH 7.9 with 200 ng of sonicated salmon sperm DNA as unspecific competitor. In competition experiments specific oligonucleotides were added prior to the addition of the extract. When affinity-purified fractions were analyzed, 50 ng of unspecific competitor and 0.1 mg/ml bovine serum albumin were added. The mixture was preincubated at room temperature for 15 min before 5 /d of ^P-labeled oligonucleotides (10 4 cpm) were added. The incubation was continued for another 15 min and the resulting complexes were electrophoretically resolved at 100 V for 90 min at room temperature on a 4% nondenaturing polyacrylamide gel in 0.25XTBE (1 XTBE = 90 mM Tris base, 90 mM boric acid, 2.5 mM EDTA, pH 8.3). Before being exposed to X-ray films, the gels were fixed in 10% acetic acid and dried.
For methylation interference assay on the labeled upper strand of BABS, 50 /ig of the deletion plasmid [Blwt (-95/-37)-TG] was linearized with HindHI which cuts at position -95. The digested DNA was treated with 24 U of calf intestinal alkaline phosphatase for 30 min at 37° C, 10 min at 75° C and isolated by phenol/chloroform extraction and ethanol precipitation. The DNA was then cleaved with Xho I which cuts in the polylinker 20 bp downstream of position -37. For the lower strand of BABS, 30 /ig of the deletion plasmid was linearized with Eco RI which cuts in the polylinker 26 bp downstream of position -37. After dephosphorylation of the DNA the fragment was cleaved with HindHI. The dephosphorylated DNA fragments were isolated by gel electrophoresis. 10 n\ of each fragment (about 50 ng) was treated with 10 U of T4-polynucleotide kinase in a 20 /il reaction containing 50 /tCi of y-^P-ATP for 30 min at 37° C and then ethanol precipitated. A portion of the restriction fragments (5 X 10 5 -10 6 cpm) were treated with dimethyl sulfate (DMS) for 3 min at room temperature (23) . The methylated fragments were recovered by two precipitations with ethanol and used in a preparative binding reaction with 30 ng of affinity purified protein (one cycle over an affinity column), 500 ng of salmon sperm DNA and 10 5 cpm of partially methylated DNA. Free and complexed DNA were recovered from a polyacrylamide gel, treated with piperidine and the cleavage products analyzed on a sequencing gel (23).
For UV cross-linking a mixture as used for gel retardation assay containing 9 /xg protein was spotted onto a piece of parafilm, put on ice and photo-cross-linked under a UV lamp (A emission = 254 nm) for 20 min at a distance of 6 cm from the UV source. After UV irradiation the probes were mixed with an equal volume of loading buffer, boiled for 3 min and electrophoresed on a 10% SDS-polyacrylamide gel (18) . The gel was fixed in 10% acetic acid, dried and exposed for autoradiography.
RESULTS

BABS, a Regulatory Element of the Bl Vitellogenin Gene Conferring High in vitro Transcriptional Activity
Various 5' deletions (-240 to -48) of the Bl vitellogenin gene were tested in vitro for their transcriptional efficiency with rat liver nuclear extract. These fragments were inserted at their natural Bgin site (ending at position -37 of the Bl vitellogenin gene) in front of a TATA box present in the vector PL-TG previously used to identify regulatory elements by in vitro transcription assays. This vector contains a G-free cassette of 400 bp that allows easy detection of correctly initiated transcripts (6) . In all reactions a construct containing the adeno major late promoter linked to a shortened G-free cassette of 200 bp was included as an internal control to standardize the transcriptional activity of various reactions. Fig. 1 a illustrates that in rat liver nuclear extracts 5' deletion constructs extending to -55 yield high positive transcriptional activity comparable to the adeno major late promoter in clone pML (C 2 AT), 9 (24) . Deletion from -240 to -55 gives an overall reduction of activity by a factor of 3 whereas a further deletion of 7 bp to position -48 reduces the activity at least lOfold, to the level observed by a construct containing a polylinker sequence in place of the Bl vitellogenin gene insert (PL).
As the sequence between -55 to -37 of the Bl vitellogenin gene mediates high in vitro transcriptional activity, we analyzed the sequence specific interactions at this position. In a first approach we incubated the labeled oligonucleotide extending from -55 to -37 (Blwt) with the rat liver nuclear extract used for the in vitro transcription. In a gel retardation assay complex formation is seen (Fig. 2 a) that is competed by a 250fold excess of the unlabeled Blwt oligonucleotide (lane 5), but is resistant to the same amount of heterologous probe (lane 6). At low input of homologous competitor the complexes can be resolved in two species (see also Fig. 4 b) . This suggests that formation of complex 1 requires higher concentration of oligonucleotides. The gel retardation assay establishes that the region -55 to -37 of the Bl vitellogenin gene is specifically recognized by nuclear proteins present in the rat liver. We refer to the recognized sequence as the B-activator binding site (BABS). To further document sequence specific interaction at BABS we made a methylation interference assay to identify guanines and adenines in the DNA binding site that, when methylated, interfere with lower upper
Figure 2. BABS specifically interacts with proteins from rat liver nuclei a) Sequence specificity of the complexes 1 and 2. Three /ig of rat liver nuclear protein were incubated with ^P-labdcd Blwt oligonucleotide and 100 ng of salmon sperm DNA (lane 1). In addition lanes 2-5 contain the indicated fold molar excess of unlabeled homologous Blwt oligonucleotide as competitor (COMP), whereas in lane 6 a 250foW molar excess of an unrelated oligonucleotide containing the ERE (11) was included. The retarded complexes, 1 and 2, are indicated, b) Methylation interference assay. Preparative binding reactions were carried out with partially methylated DNA fragments containing BABS labeled either on the lower, non-coding strand (lanes 1 to 3) or on the upper, coding strand (lanes 4-6). The partially methylated DNA was cleaved either prior to the binding reaction (G, lanes 1 and 6) or after binding recovered from the bound (B, lanes 2 and 5) and free (F, lanes 3 and 4) fraction. The result of the assay is summarized on the sequence of the 5' flanking region of the Bl vitellogenin gene containing BABS. Methylated guanine residues interfering strongly (•) and weakly (O) with proteins from rat liver and their location in the BABS are marked. Brackets indicate the region protected from DNase I digestion (footprint analysis, data not shown).
protein binding (23) . Partially methylated DNA either labeled at the lower or upper strand was incubated with rat liver nuclear proteins and separated in free and complex bound DNA by gel retardation analysis. The DNA recovered was treated with piperidine to visualize positions of methylated purines. Fig. 2 b demonstrates that the guanines in the upper strand at -53, -47 and -45 (lanes 4 to 6) and in the lower strand at -52, -50 and -44 (lanes 1 to 3) are not or less methylated in the complexed compared to the free DNA. This is clear evidence that methylation of these sites interferes with binding.
To further prove sequence specific recognition of BABS we made a footprint analysis in the 5' flanking region. The data obtained agreed with a recent report (25) and therefore are just included as a summary in the sequence shown in Fig. 2 b. The protected area includes the guanines shown to be important in the methylation interference assay and corresponds to the A site described by Corthesy et al. (25) .
Based on these binding studies, we conclude that the sequence between -55 and -37 is recognized specifically by nuclear proteins from rat liver.
Two Single Point Mutations Introduced into BABS Destroy its Functional Activity in vitro
Examination of the sequence from -55 to -37 of the Bl vitellogenin gene reveals a palindromic sequence from -53 to -44 ( Fig. 1 b) . As many transcription factors recognize palindromic sequences (2, 26), we speculated that the sequence from -53 to -44 is sufficient to confer positive transcriptional activation. To verify this assumption, we inserted the corresponding oligonucleotide into PL-TG, and tested its activating potential in vitro using nuclear extract from rat liver. The data given in Fig. 3 a show that this sequence mediates high transcriptional activity (lane 1) identical to the construct extending from -55 to -37 ( Fig. 1, comparison not shown directly) .
To define the sequence requirements for a functional Bactivator binding site (BABS), we introduced single point mutations, i. e. transitions in BABS, and analyzed the transcriptional activity of these mutants in a rat liver nuclear extract. As illustrated in Fig. 3 a, two point mutations, mt 7 and mt 9, abolish B-activator function. Quantification by densitometry (Fig. 3 b) revealed that these two point mutations reduce the activity at least 5fold, whereas mutations at other positions, i. e. mt 2, 4, 5, 6 and 8 interfere with the function at most twofold.
DNA Elements Similar to BABS are Present in Animal Viruses
Comparing BABS with known regulatory sequences we observed that BABS is similar to the USF/MLTF binding site of the adenovirus major late promoter (27, 28, 29) since the CACGTG core sequence of the USF/MLTF site corresponds in BABS to CACATG (see Fig. 4a ). Furthermore, a BABS related sequence was also detected in the hepatitis B virus enhancer (Fig. 4a) .
To investigate whether these BABS related DNA sequences interact with the same proteins, we compared the ability of the oligonucleotides listed in Fig. 4 a to compete binding to BABS in rat liver nuclear extract. were analyzed in a rat liver nuclear extract with the internal control pML cas 9 (see Fig. 1 ). For comparison the transcription vector PL-TG (PL) was used, b) The transcriptional activity of the various constructs was compared to Bl-O and quantified by densitometry using the internal control pML cas 9 as standard. The data are the mean of at least 4 independent experiments. The broken lines indicate the standard deviations.
limiting amounts of competitor complex 2 is preferentially disappearing. At high competitor input both complexes disappear (data not shown). In contrast the USF/MLTF binding site derived from the adeno major late promoter selectively competes complex 1 whereas the intensity of complex 2 is unaffected (lane 6 and 7). The factor bound in complex 2 we refer to as the Bactivator protein (BAP). These binding data establish that the elements found in the Xenopus Bl vitellogenin gene and the hepatitis B virus enhancer bind the same factors whereas the USF/MLTF binding site is able to bind a subset of these factors. These results were confirmed by gel retardation competition assays containing either the hepatitis B virus or the adenovirus element as labeled probes in the binding assay (data not shown).
To analyze whether the BABS related sequences as found in the hepatitis B virus enhancer and the adeno major late promoter (Fig. 4 b) and in the in vitro transcription assays (Fig. 5) . The Hindlll and Bglll or BamHI sites were added to allow cloning in PL-TG. The numbers refer to the position in the promoter or the enhancer. The sequences were taken from ref. 41, 35, 29 for the Blwt, HBV and USF oligonucleotides, respectively. The black dots denote nucleotides, that do not agree with the sequence found in Blwt. The core sequence in the USF/MLTF binding site is underlined, b) Nuclear proteins prepared from rat liver were incubated with 32 P-labeled Blwt oligonucleotide, separated on a polyacrylamide gel and the retarded oligonucleotides, forming complexes 1 and 2 visualized by autoradiography (lane 1). Lanes 2-7 contain the indicated unlabeled oligonucleotides as competitor. Numbers indicate the molar excess of competitor versus probe used.
can also increase the transcriptional activity, we replaced the Xenopus sequence in the transcription vector with these homologues and analyzed their transcriptional potential. Using a rat nuclear liver extract, we observed that both sequences mediate increased transcriptional activity. The HBV element increased the activity 27fold above the level observed with the polylinker construct, whereas the USF/MLTF binding site containing template gave a lOfold increase, similar to the 13fold stimulation observed by BABS of the vitellogenin Bl gene. To compare these regulatory elements we added the different oligonucleotides as competitors into the in vitro transcription reaction. The quantification of these competition assays revealed that the activity of the transcription vector containing the Xenopus B-activator binding site (Fig. 5) is inhibited by 90% upon the addition of the homologous oligonucleotide as well as of the BABS homologue as found in the hepatitis B virus enhancer. No inhibition but rather an increase by a factor of three is observed with the USF/MLTF binding site as competitor. Using the template with the HBV element, the homologous oligonucleotide and the one containing the Xenopus element show efficient inhibition, whereas the USF/MLTF binding site is unable to compete. Experiments with the template containing the USF/MLTF binding site, revealed that the homologous oligonucleotide does inhibit the transcription 5fold, whereas transcriptional activity is reduced only 2fold upon adding the vitellogenin or the HBV containing oligonucleotide as competitor.
In summary, these transcription experiments confirm the conclusions drawn from the binding studies. Both approaches demonstrate that the Xenopus Bl vitellogenin gene and the hepatitis B virus enhancer contain BABS as a common regulatory element, recognized by the same transcription factors and this cis-element is distinct from the USF/MLTF binding site found in the adenovirus major late promoter.
Phosphorylation of the B-activator Protein, BAP, is Absolutely Required for DNA Binding
It has been reported that transcription factors may be subjected to posttranslational modification, e. g. glycosylation or phosphorylation (2) . To analyze whether the B-activator protein (BAP) binding to BABS is glycosylated, rat liver nuclear extract was chromatographed on a wheat germ lectin agarose column. All the BAP activity as measured by gel retardation assay was in the flow-through fraction, whereas HNF1 known to be glycosylated (10) was efficiently retained on the column (data not shown) as measured by HP1 binding (6) . This implies that BAP is not glycosylated.
To examine the importance of phosphorylation we treated crude rat liver nuclear extract with potato acid phosphatase and assayed for DNA binding activity by gel retardation assay. As Fig. 6 Bi-wt illustrates, binding activity is completely lost upon phosphatase treatment (compare lane 1 with lane 2). This effect is specific since in the presence of 20 mM sodium molybdate, a specific phosphatase inhibitor, binding activity is retained (lane 3). Identical results were obtained by using the oligonucleotide probe from the hepatitis B virus enhancer (data not shown). In contrast, the binding of USF/MLTF to the adeno major late promoter is not affected by phosphatase treatment (lanes 4 to 6). This holds also true for the binding of the liver-specific transcription factor HNF1 that was assayed as an additional control in the same extract (lanes 7 to 9). We conclude that phosphorylation of BAP is absolutely required for its DNA binding activity.
Molecular Weight and Purification of the B-activator Protein (BAP)
UV cross-linking was used to estimate the molecular mass of the B-activator protein (BAP) directly in a crude nuclear extract. In contrast to several other procedures for UV cross-linking, we found it unnecessary to incorporate BrdU for thymidine in preparing the probe. Rat liver nuclear extract was incubated with the labeled oligonucleotide Blwt and irradiated with UV light to generate covalent links between the DNA and BAP. Analysis on an SDS polyacrylamide gel revealed three polypeptides with apparent molecular weights of 73 kd, 51 kd and 39 kd (Fig. 7) . If a 250fold molar excess of unlabeled B-activator oligonucleotide was added, the 73 kd band disappeared specifically, while competition with the same amount of heterologous oligonucleotides had no effect. This demonstrates that the 73 kd band represents a specific interaction. This finding was confirmed by using a highly purified preparation of BAP, whose UV crosslinking revealed only the 73 kd band (Fig. 7) , whereas the 51 kd and 39 kd band corresponding to nuclear proteins interacting nonspecifically with the probe were absent. Again, the interaction with the 73 kd protein is specific as it is competed exclusively with the homologous probe. As we did not observe a cross-linked protein that might represent USF/MLTF, we assume that under the conditions used this factor cannot be covalently bound to its target sequence. By assuming that the cross-linked Blwt oligonucleotide contributes a molecular weight of 15 kd, we estimate that BAP has a molecular weight of 58 kd.
As the B-activator binding site binds BAP as well as USF/MLTF (see above)
, it was important to analyze whether these two proteins can be separated during the purification. Gel retardation assays with the Blwt oligonucleotide as a probe reveals in a highly purified BAP preparation that has been fractionated by 3 cycles of DNA affinity columns with BABS as ligand, complex 2 exclusively (Fig. 8, lane 2) . This DNAprotein interaction can specifically be competed by Blwt oligonucleotide 0ane 3) but not by the USF/MLTF binding site (lane 4) or an unrelated oligonucleotide (lane 5). This suggests that we succeeded to separate BAP from USF/MLTF. The loss of USF/MLTF upon purification of BAP is also evident in gel retardation experiments using the USF/MLTF binding site as probe: High specific binding is found in the heparin-Sepharose fraction (lanes 6-9) whereas no distinct complexes can be found in the highly purified BAP preparation (lanes 10-13) .
DISCUSSION
The B-activator Binding Site, BABS, a Novel Promoter Element Increasing Transcription in vitro
In the present study, we have used an in vitro transcription system derived from rat liver nuclei (15) using a G-free reporter cassette (24) , to establish functional promoter regions of the Xenopus Bl vitellogenin gene. Using this heterologous approach we have shown that a promoter segment, the B-activator binding site (BABS), extending from position -55 to -37 of the Bl gene, confers most of the activity observed in in vitro transcription. The same region has very recently been identified as the major positive acting promoter element, VA element, in transfections of Bl vitellogenin constructs into Xenopus cells (30) . This homologous assay proves that BABS is of functional importance in Xenopus cells in vivo. BABS can further be reduced to 10 bp that are sufficient in the in vitro transcription assay if inserted in front of the TATA box derived from the Xenopus albumin gene (6). As we have not systematically mutated the region surrounding these 10 bp, we cannot rigorously exclude that other sequences flanking the element are important. In accordance with our recent experiments analyzing HP1, a regulatory element conferring liver-specific transcriptional activity (31), we assume that BABS just requires the TATA box as an obligatory element for its activity.
Mutational analysis of BABS (Fig. 3) has shown that at least two positions in the 10 bp element are essential for its function in the in vitro transcription system. This is a minimum estimate, as we have introduced only transitions that might be less harmful than changes from pyrimidines to purines, i. e. transversions. This may also explain why some guanines found to be important in the methylation interference assay (Fig. 2 b) can be replaced by adenines without loss of transcriptional activity. The interpretation of the mutational analysis is further complicated by our finding that BABS as found in the Bl vitellogenin gene is also recognized by the transcription factor USF/MLTF. Therefore, some of the transcriptional activity mediated by BABS may be influenced by USF/MLTF binding (see below). This implies that some point mutations may lead to a change in the balance of BAP and USF/MLTF binding. This can best be exemplified by mutant 5 which generates the perfect core sequence of the USF binding site, CACGTG.
The sequence as found in BABS has palindromic properties with 5' GC 3' on its ends and the palindromic CATG internal region (Fig. 1) . However, BABS function is not mediated by a perfect palindrome as mutations at corresponding sites of the palindrome, behave differently: Changes as made in mutants 7 and 9 are critical for function, whereas those present in mutant 2 and 4 hardly interfere with the activity.
Gel retardation experiments have shown that the B-activator binding site specifically interacts with proteins from rat liver nuclei. We have confirmed these data by footprint experiments (data not shown) and these findings agree with a recent report (25) which describes three protected sites (A, B and C) in the Bl vitellogenin promoter. Site A, containing BABS we have identified in this paper, did not mediate any functional activity in these experiments whereas the other sites play a crucial role in in vitro transcription. Our data give direct evidence that site A confers increased transcriptional activity. The fact that the addition of an oligonucleotide containing the BABS sequence inhibits specifically the in vitro transcription implies that the interaction with BABS linked to the promoter is an essential step in transcriptional activation.
A comparison of the BABS sequence with the recognition sites of known transcription factors (32, 33) revealed some homology between BABS and the USF/MLTF binding site of the adeno major late promoter as well as a binding site in the hepatitis B virus enhancer. Competition experiments using the gel retardation assay (Fig. 4 b) as well as the in vitro transcription (Fig. 5) , established that the hepatitis B virus (HBV) enhancer oligonucleotide binds similar if not identical transcription factors as BABS found in the Bl vitellogenin gene. Since the precise role of HBV in hepatocellular tumorigenesis is unclear (34) , it is of particular interest to elucidate regulatory elements that might control the HBV life cycle and regulate its gene expression. Recently, Ben-Levy et al. (35) were able to show that a variety of cellular factors interact with the HBV enhancer, a possible candidate for the activation of host protooncogenes, thereby inducing tumor formation. Interestingly, in the HBV enhancer the BABS element we have identified is located close to a NF-I binding site (35) , a comparable situation as reported for the Bl vitellogenin gene (25) .
Our data establish that BABS is related but distinct from the USF/MLTF binding site found in the adenovirus major late promoter. As USF/MLTF binding sites have also been detected in the promoters of cellular genes, e. g. the mouse metallothionein I gene (36) , the rat y fibrinogen gene (37, 38) and the Xenopus gene coding for TFITIA (39, 40) we speculate that some of these sites might also interact with BAP. Analyzing the promoters of the other three vitellogenin genes of Xenopus, we note that the B2 gene which is most closely related to the Bl gene (41) contains the identical sequence present in BABS of the Bl gene, whereas related sequences are present in the A1 and A2 genes. Recent experiments have shown that the sequence -57 to -40 of the A2 vitellogenin gene inserted into PL-TG confers high in vitro transcription, that can specifically be competed by a BABS oligonucleotide (unpublished data). This suggests that all 4 Xenopus vitellogenin genes known to be coordinately expressed contain BABS as common promoter element.
BAP, the Factor Recognizing the B-activator Binding Site
Clearly, BAP is a transcription factor distinct from USF/MLTF. This is proven by our purification data as well as by the various characteristics that distinguish BAP from USF/MLTF. These differences include the molecular weight, 58 kd versus 43 -46 kd (29, 42) and the need of phosphorylation for DNA binding for BAP but not for USF/MLTF. The distinction between BAP and USF/MLTF can also be deduced from a recent analysis of the Bl vitellogenin promoter (25) : The protein binding to site A containing BABS (see above) cannot be competed by a USF/MLTF binding site. This observation is consistent with our finding that BABS binds two distinct proteins in the gel retardation assay (Fig. 4 b) , only one of which can be competed by USF/MLTF binding site competition. Thus a footprint is expected to persist using USF/MLTF binding site as competitor.
The vitellogenin genes were shown to be active only in liver cells (3, 4) , raising the possibility that the B-activator binding site carries the recognition sequence for a liver-specific transacting factor, like HP1 (6), i. e. the HNF1/LFB1 binding site (7, 8, 9, 10) . In vitro transcription experiments revealed that BABS mediates transcriptional activation not only in extracts from hepatic cells but also in extracts from many other sources including HeLa, MCF-7 and Ltk~ cells (data not shown). Gel retardation assays allowed us to detect the formation of various different complexes in all these extracts (data not shown). Therefore, we conclude that BABS is recognized by factors that form a family of related proteins. This family includes USF/MLTF known to be heterogeneous (42, 43) . Further characterization is needed to decide whether BAP as found in rat liver nuclear extract is a hepatocyte-specific or a ubiquitous transcription factor.
A common feature of many transcription factors is that they exist as phosphoproteins or glycoproteins. Therefore, their function could be conceivably regulated by phosphorylationdephosphorylation or glycosylation-deglycosylation events. Here, we provide evidence that phosphorylation is absolutely necessary for DNA binding activity of BAP. We speculate that BAP is activated by protein kinases that might participate in controlling genes containing BABS in their promoter. Phosphorylation dependent DNA-binding has also been reported for the transcription factor CREB (44) and the serum response factor (20, 45) .
One essential approach towards understanding the molecular regulation of the vitellogenin genes is to purify the trans-acting factors interacting with promoter elements of these genes. In this paper we describe the properties of the trans-acting factor BAP which allow its purification. We show that BAP can efficiently be separated from USF/MLTF mainly by using 3 cycles of chromatography on DNA affinity columns with BABS as ligand (Fig. 8) .
Recognition of the Same Regulatory Element by Different Transcription Factors
The B-activator binding site, BABS, is recognized by two different proteins, BAP and USF/MLTF. This conclusion is based primarily on binding assays: Gel retardation experiments indicate that both BAP and USF/MLTF are able to bind to BABS, thereby generating DNA-protein complexes of different mobilities (complex 2 and 1 in Fig. 4 b) . Both these complexes are competed by adding the BABS containing oligonucleotide, but upon adding the USF/MLTF binding site complex 1 is competed exclusively. As the mobility of the remaining complex in the competition experiments is not changed, we assume that BAP and USF/MLTF bind in a mutually exclusive manner.
In agreement with the binding studies, an USF/MLTF binding site oligonucleotide cannot compete the transcriptional activity of a template containing BABS as regulatory element. In fact, in all experiments an increase in activity was observed. This may suggest that USF/MLTF binding leads to a less efficient transcriptional complex than the binding of BAP. It was quite surprising that BABS was not sufficient to compete efficiently the transcription of a USF/MLTF binding site template even when up to 500 ng of oligonucleotide per reaction were used. This may be explained by the observation that USF/MLTF is heterogeneous (42, 43) and possibly only some forms are competed by BABS. This agrees with the observation that in gel retardation assays the USF/MLTF binding site forms complexes that cannot be competed by the BABS of the Bl vitellogenin gene (Fig. 8 lanes  6 and 7) .
Binding data suggest that the regulatory element found in the hepatitis B virus enhancer is equivalent to BABS as found in the Bl vitellogenin gene. Obviously, it also binds USF/MLTF and BAP. However, the in vitro transcription assays show some distinct features compared to BABS as found in the Bl vitellogenin gene: The USF/MLTF binding site as competitor does not lead to an increase in in vitro transcription of the HB V template as found for the Blwt template. A further distinction between the HBV element and BABS as found in the vitellogenin gene is given by the fact that the HBV template is 3-fold more active in the in vitro transcription assay as compared to the corresponding vitellogenin gene construct.
In conclusion, our data show that a short DNA stretch of the Bl vitellogenin promoter has the potential to interact with various transcription factors. Similar situations have been reported for other promoter and enhancer elements (2, 46) . The balance in binding of the various factors may allow the complex regulatory pattern.
